Outcome
    Moderate Evidence

    NMN for NAD+ Restoration

    Raising NAD is the one thing NMN has clearly been shown to do in humans.

    Overview

    The question of whether NMN actually raises NAD+ in humans has a clearer answer than most of the longevity field. In 42 healthy older Japanese men, 250 mg daily for 12 weeks raised whole-blood NAD+ metabolites versus placebo.
    The same trial also found improved gait speed and right-hand grip strength, while muscle insulin sensitivity and most other metabolic measures did not differ significantly. That split is the honest summary: the biochemical endpoint moved reliably, the functional endpoints moved partially, and the metabolic endpoints mostly did not. So NMN does what it claims at the level of NAD+ chemistry. Whether raising blood NAD+ metabolites translates into the health outcomes the category is marketed on remains unproven, and one small trial in one demographic cannot settle it.

    Verdict

    Likely effective

    A placebo-controlled trial in 42 older men showed NMN 250 mg daily raised whole-blood NAD+ metabolites over 12 weeks. Functional gains were partial and most metabolic measures were unchanged.

    How It Works

    NAD+ is the electron carrier at the centre of energy metabolism and the required cofactor for sirtuins and PARP enzymes. Tissue NAD+ declines with age, which is the premise the entire category rests on.
    NMN sits one enzymatic step from NAD+, converted by NMN adenylyltransferase. There has been genuine scientific argument about whether oral NMN is absorbed intact or dephosphorylated to nicotinamide riboside first; the trial evidence shows blood NAD+ metabolites rise either way, so the route matters less than the outcome. The unresolved question is compartments. Whole-blood NAD+ metabolites are what was measured, and they are not the same as NAD+ inside muscle, brain or liver mitochondria, which is where the proposed benefits would have to originate.
    Pathway
    NMN converted to NAD+ by NMN adenylyltransferase
    Measured endpoint
    Whole-blood NAD+ metabolites
    Unmeasured
    Intracellular NAD+ in muscle, brain and liver
    Functional signals
    Gait speed and right-hand grip strength
    Null findings
    Muscle insulin sensitivity and most metabolic measures

    Dosing & Protocol

    The linked trial used 250 mg daily for 12 weeks, which is at the lower end of what is sold commercially. Higher doses of 500 to 1000 mg appear in other studies without clear evidence that more produces more.
    ContextDoseFormTiming
    Trial protocol250 mg dailyOral NMNMorning, 12 weeks
    Common commercial range250-500 mg dailyOral NMN capsules or powderMorning
    Upper doses studied elsewhereup to 1000 mg dailyOral NMNMorning, split if preferred
    Assessment window12 weeksOral NMNDaily
    1. 1

      Decide what you are actually testing· Week 0

      NAD+ metabolites are a biomarker. Pick a functional measure such as gait speed or grip strength you can retest.

    2. 2

      Verify third-party purity· Before buying

      NMN has had significant analytical quality problems and a contested regulatory status in some markets.

    3. 3

      Take 250 mg daily in the morning· Weeks 1-12

      This matches the trial protocol; higher doses have no demonstrated advantage.

    4. 4

      Keep the basics in place· Ongoing

      Resistance training and sleep influence the same functional endpoints far more strongly.

    5. 5

      Retest at 12 weeks· Week 12

      Match the trial duration before judging. Stop if nothing measurable has changed.

    Biomarker is not benefit

    Raising blood NAD+ metabolites is well supported. That an elevated biomarker produces longer or healthier life is not, and no trial has tested it.

    Evidence

    The linked placebo-controlled trial gave 250 mg daily to 42 healthy older Japanese men for 12 weeks. Whole-blood NAD+ metabolites rose, gait speed and right-hand grip strength improved, and muscle insulin sensitivity and most other metabolic measures were unchanged.

    Placebo-controlled human trial linked to this pairing.

    Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men

    Score: 6/10
    2022n=42

    Igarashi M, Nakagawa-Nagahama Y, Miura M +13 more

    Chronic NMN supplementation elevated blood NAD+ levels and altered muscle function in healthy older men.

    View source
    Best available evidence
    Placebo-controlled trial, n=42, npj Aging 2022
    Primary positive result
    Elevated whole-blood NAD+ metabolites
    Secondary signals
    Gait speed and right-hand grip strength
    Null results
    Muscle insulin sensitivity and most metabolic measures
    Main limitation
    Small, single-demographic sample; grip effect on one hand only

    Safety

    Short-term human trials report good tolerability at 250 to 1000 mg daily with no serious adverse events. The genuine gap is duration: the longest trials run months, while people take it for years.

    Cautions

    No long-term human safety data beyond several months
    Product purity varies; third-party testing matters
    Regulatory status is contested in some markets
    Theoretical concern about fuelling existing cancers is unresolved
    Avoid during active cancer treatment without oncology advice

    Interactions & Conflicts

    There are no well-documented drug interactions. The entries below are mechanistic considerations and redundancies rather than established clinical conflicts.
    Interacts withSeverityMechanismAction
    Nicotinamide riboside or high-dose niacinamide
    low
    		Same NAD pathway; effects are redundantUse one NAD precursor
    Active cancer therapy
    moderate
    		NAD supports the metabolism of proliferating cells; unresolved theoreticallyDiscuss with your oncologist before use
    Resveratrol
    low
    		Commonly stacked for sirtuin activation; no human outcome evidenceOptional; do not expect additive benefit
    Metformin
    low
    		Overlapping metabolic pathways with unclear net directionNo action needed; monitor as usual

    References

    1. Igarashi M et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. npj Aging. 2022

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.